Summit Therapeutics (SMMT) Competitors $18.67 +0.80 (+4.48%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SMMT vs. TAK, BNTX, TEVA, BGNE, MRNA, VTRS, GMAB, RDY, SRPT, and CTLTShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Summit Therapeutics vs. Takeda Pharmaceutical BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Takeda Pharmaceutical (NYSE:TAK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Do analysts recommend TAK or SMMT? Summit Therapeutics has a consensus price target of $33.33, indicating a potential upside of 78.54%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals & insiders believe in TAK or SMMT? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, TAK or SMMT? Takeda Pharmaceutical has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500. Which has better earnings and valuation, TAK or SMMT? Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.55T0.01$994.06M$0.5822.71Summit Therapeutics$700K19,668.79-$614.93M-$0.28-66.68 Does the MarketBeat Community favor TAK or SMMT? Summit Therapeutics received 201 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.22% of users gave Summit Therapeutics an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% Summit TherapeuticsOutperform Votes30158.22% Underperform Votes21641.78% Is TAK or SMMT more profitable? Takeda Pharmaceutical has a net margin of 6.49% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 10.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Summit Therapeutics N/A -85.42%-52.66% Does the media refer more to TAK or SMMT? In the previous week, Summit Therapeutics had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 11 mentions for Summit Therapeutics and 1 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat Summit Therapeutics' score of 0.67 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTakeda Pharmaceutical beats Summit Therapeutics on 10 of the 18 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.77B$6.70B$5.20B$9.14BDividend YieldN/A3.00%5.12%4.29%P/E Ratio-66.6810.6087.0517.14Price / Sales19,668.79193.811,138.53122.78Price / CashN/A57.1643.2337.84Price / Book169.735.134.804.78Net Income-$614.93M$151.58M$120.46M$225.43M7 Day Performance-0.05%0.01%-0.84%-0.68%1 Month Performance-1.74%-3.72%14.79%1.03%1 Year Performance687.76%9.07%29.53%15.71% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics3.1322 of 5 stars$18.67+4.5%$33.33+78.5%+654.0%$13.77B$700,000.00-66.68105TAKTakeda Pharmaceutical4.5308 of 5 stars$13.33-0.7%N/A-6.8%$42.41B$28.20B23.1449,281BNTXBioNTech2.025 of 5 stars$115.76-3.8%$140.76+21.6%+7.4%$27.52B$3.04B-56.016,133TEVATeva Pharmaceutical Industries1.8599 of 5 stars$16.77+1.6%$19.67+17.3%+110.8%$19.00B$16.77B-19.7937,851Options VolumeBGNEBeiGene2.7991 of 5 stars$176.95-1.3%$253.69+43.4%+0.2%$17.24B$2.46B-21.7710,600MRNAModerna4.2655 of 5 stars$41.63-0.5%$79.50+91.0%-58.5%$16.02B$5.06B-7.195,600VTRSViatris1.8751 of 5 stars$12.74+0.9%$13.67+7.3%+17.6%$15.21B$15.05B-17.0738,000GMABGenmab A/S4.237 of 5 stars$20.21+0.2%$45.20+123.7%-35.4%$13.37B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.1362 of 5 stars$14.76+2.1%$17.00+15.2%+14.1%$12.32B$299.87B22.9527,048SRPTSarepta Therapeutics4.7799 of 5 stars$127.00+2.7%$178.71+40.7%+25.8%$12.13B$1.64B98.971,314Positive NewsCTLTCatalent2.5919 of 5 stars$63.47+0.6%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading Volume Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors Moderna Competitors Viatris Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Sarepta Therapeutics Competitors Catalent Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SMMT) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
